11.1 Local Anesthetics: Chemistry, Mechanism & Systemic Toxicity

11.1 Local Anesthetics: Chemistry, Mechanism & Systemic Toxicity

Local anesthetics (LAs) are among the most frequently utilized classes of perioperative pharmaceuticals. They are administered for local infiltration, peripheral nerve blockade, intravenous regional anesthesia (Bier block), and neuraxial (spinal and epidural) anesthesia. For the Certified Anesthesia Technologist (Cer.A.T.T.), mastering the chemical architecture, electrophysiological mechanisms, physicochemical determinants, and life-threatening toxicity profiles of local anesthetics is essential for anticipating clinical needs, preparing emergency equipment, and participating rapidly in resuscitation protocols.

---

Chemical Architecture: Esters vs. Amides

All clinically deployed local anesthetics share a tripartite fundamental chemical structure:

1. Lipophilic Aromatic Ring (Benzene Ring): Confers lipid solubility, enabling the molecule to traverse the hydrophobic perineural lipid bilayer and axonal membrane.
2. Intermediate Chain (Alkyl Chain): Connects the aromatic head to the amine tail. The nature of this intermediate linkage divides all local anesthetics into two distinct pharmacologic classes: esters (-COO-) or amides (-NHCO-).
3. Hydrophilic Group (Tertiary Amine): A weak base that accepts hydrogen ions, allowing the molecule to exist in an ionized, water-soluble form suitable for commercial aqueous solution preparation and extracellular distribution.

   [Lipophilic Benzene Ring] --- [Intermediate Chain] --- [Hydrophilic Tertiary Amine]
                               (Ester or Amide Link)

Ester Local Anesthetics

• Representative Agents: Procaine (Novocain), Tetracaine (Pontocaine), Cocaine, Benzocaine, and Chloroprocaine (Nesacaine).
• Metabolism: Rapidly hydrolyzed in the blood by plasma pseudocholinesterase (butyrylcholinesterase). Metabolism is organ-independent and exceptionally fast, yielding very short plasma elimination half-lives (chloroprocaine half-life is < 1 minute).
• Allergic Potential: Hydrolysis of ester local anesthetics yields para-aminobenzoic acid (PABA) as a primary metabolic byproduct. PABA is an immunogenic compound capable of triggering true Type I, IgE-mediated anaphylactic reactions. Patients with documented hypersensitivity to one ester agent typically exhibit cross-reactivity across the entire ester class.
• Special Note on Cocaine: Cocaine is an ester local anesthetic extracted from Erythroxylum coca. Uniquely among local anesthetics, it undergoes significant hepatic metabolism in addition to plasma pseudocholinesterase hydrolysis. Furthermore, cocaine is the only local anesthetic that produces intense intrinsic vasoconstriction by blocking the presynaptic reuptake of norepinephrine and dopamine via the norepinephrine transporter (NET), resulting in systemic sympathetic stimulation (tachycardia, severe hypertension, coronary vasospasm, and dysrhythmias).

Amide Local Anesthetics

• Representative Agents: Lidocaine (Xylocaine), Bupivacaine (Marcaine, Sensorcaine), Ropivacaine (Naropin), Mepivacaine (Carbocaine), and Prilocaine (Citanest).
• Metabolism: Undergo complex enzymatic biotransformation in the liver mediated primarily by the Cytochrome P450 (CYP450) microsomal enzyme system (predominantly CYP1A2 and CYP3A4). Consequently, amide clearance is strictly dependent on hepatic blood flow and intrinsic liver function. Severe hepatic cirrhosis, congestive heart failure, or co-administration of CYP inhibitors (e.g., cimetidine, erythromycin) markedly prolongs elimination half-lives and escalates systemic accumulation risk.
• The "Two 'I's" Mnemonic Rule: A reliable nomenclature rule identifies the chemical class: amide local anesthetics contain two letter "i"s in their generic name (e.g., lidocaine, bupivacaine, ropivacaine, mepivacaine, prilocaine). Ester local anesthetics contain only a single letter "i" (e.g., proca****ine, tetracaine, chloroproca****ine, benzocaine, cocaine).
• Allergic Potential: True allergic reactions to amide local anesthetics are exceptionally rare (accounting for < 1% of adverse events). True allergic responses to amide solutions are almost universally triggered by methylparaben, an antimicrobial preservative chemically homologous to PABA that is added to multi-dose vials. Preservative-free (single-dose) ampules or vials eliminate this risk.

---

Mechanism of Action: Sodium Channel Electrophysiology

Under baseline resting conditions, the neuronal axon maintains a negative intracellular resting membrane potential of approximately -70 mV, generated by the active Na+/K+ ATPase pump and background potassium leak channels. When a nociceptive stimulus depolarizes the axonal membrane toward threshold (~ -55 mV), voltage-gated sodium channels (Nav channels) open, allowing a massive, rapid influx of positively charged sodium ions (Na+) that drives Phase 0 depolarization.

Intracellular Receptor Binding

Local anesthetics do not block sodium channels from the extracellular surface. Instead, the molecule must enter the cell to reach its specific binding site located on the axoplasmic (inner) vestibule of the sodium channel alpha-subunit (specifically the S6 segment of domain IV):

EXTRACELLULAR SPACE:          [B]  +  [H+]  <===>  [BH+]   (Acidic / Neutral pH)
                               |
================== LIPID AXONAL MEMBRANE ==================
                               v (Only Uncharged Base B Permeates)
INTRACELLULAR AXOPLASM:        [B]  +  [H+]  <===>  [BH+]   (Re-protonation)
                                                      |
                                                      v
                                        Binds Nav Channel Inner Receptor
                                        Halts Inward Sodium Current (Na+)

1. Membrane Penetration: Only the uncharged, non-ionized free base form (B) is sufficiently lipophilic to diffuse across the axonal lipid bilayer.
2. Intracellular Re-ionization: Once within the axoplasm, the molecule re-equilibrates according to the intracellular pH (typically 7.2) into the charged, protonated cationic conjugate acid (BH+).
3. Channel Occlusion: The positively charged cationic form binds with high affinity to the receptor site inside the channel pore, physically plugging the pore and preventing sodium ion permeation.

State-Dependent & Use-Dependent Blockade

Voltage-gated sodium channels cycle continuously through three conformational states:

• Resting (Closed): Polarized membrane; channel is closed but ready to be activated.
• Active (Open): Depolarized membrane; channel pore is open, conducting Na+ influx.
• Inactive (Refractory): Inactivation gate plugs the pore; channel cannot conduct or re-open until repolarized.

Local anesthetics exhibit state-dependent affinity: they demonstrate a dramatically higher binding affinity for channels in the open (active) and inactivated states compared to the resting (closed) state. Consequently, local anesthetic blockade is use-dependent (frequency-dependent). Axons that are firing at high frequencies (such as sensory pain C-fibers transmitting acute nociceptive barrages or rapidly depolarizing cardiac myocytes) spend a greater percentage of time in the open and inactivated conformations, binding local anesthetic molecules far more rapidly and extensively than quiescent fibers.

---

Physicochemical Determinants of Clinical Behavior

The onset, potency, and duration of a local anesthetic are governed by three intrinsic physicochemical parameters: lipid solubility, dissociation constant (pKa), and protein binding.

The Impact of Tissue Acidosis and Infection

Local anesthetics are weak bases formulated commercially as acidic hydrochloride salts (pH 4.0 to 6.5) to ensure aqueous solubility and chemical stability. According to the Henderson-Hasselbalch relationship:

pH - pKa = log([Uncharged Base] / [Charged Cation])

When a local anesthetic is injected into normal physiologic tissue (pH 7.4), the extracellular fluid buffers the solution, allowing a predictable fraction of the drug to exist in the uncharged free base form (B) required to traverse the axonal sheath.

In infected, inflamed tissue (such as a dental abscess, cutaneous cellulitis, or purulent phlegmon), bacterial anaerobic metabolism and cellular necrosis generate high concentrations of lactic acid, dropping the local tissue pH to 5.5 to 6.0. In this acidotic microenvironment, the Henderson-Hasselbalch equilibrium shifts overwhelmingly to the left: hydrogen ions bind the free base, converting virtually the entire local anesthetic pool into the charged, ionized cationic form (BH+). Because charged cations cannot diffuse across the lipophilic axonal membrane, the local anesthetic is physically prevented from reaching its axoplasmic receptor, resulting in profound clinical block failure.

---

Formulations & Clinical Additives

Epinephrine (1:200,000 / 5 mcg/mL)

Epinephrine is the most widely utilized local anesthetic additive. When added to local anesthetic solutions at concentrations of 1:200,000 (5 mcg/mL) or 1:400,000 (2.5 mcg/mL), it produces multiple clinical effects:

1. Local Vasoconstriction: Activates vascular smooth muscle alpha-1 adrenergic receptors, constricting local arterioles and reducing regional capillary blood flow.
2. Prolongation of Block Duration: Slows the rate of vascular clearance from the nerve sheath, extending sensory and motor block duration by 50% to 100% (particularly for agents with moderate intrinsic vasodilator properties like lidocaine and mepivacaine).
3. Reduction of Peak Plasma Levels: Diminishes the maximum systemic blood concentration (Cmax) by 20% to 40%, directly lowering the risk of systemic toxicity.
4. Intravascular Marker: Serves as an immediate clinical indicator of accidental intravascular cannulation. During incremental test dosing (e.g., 3 mL of 1.5% lidocaine with epinephrine 1:200,000 containing 15 mcg epinephrine), an inadvertent intravascular injection triggers an immediate heart rate increase ≥ 10 to 20 bpm or systolic blood pressure surge ≥ 15 mmHg within 30 to 60 seconds.
5. Traditional Cautions: Epinephrine-containing solutions have traditionally been avoided in areas supplied by end-arteries, such as the digits, penis, nose tip, and earlobes, because of concern for vasospasm and ischemia. More recent evidence suggests low-concentration epinephrine is safe for many digital blocks, so follow the provider's plan and institutional practice.

Sodium Bicarbonate Alkalinization

Commercial local anesthetic solutions containing epinephrine are packaged at an acidic pH (3.5 to 4.5) to prevent the spontaneous oxidative degradation of epinephrine. This low pH severely limits the fraction of uncharged free base available upon injection.

To overcome this limitation, clinicians add 8.4% Sodium Bicarbonate (NaHCO3, 1 mEq/mL) immediately prior to injection:

• Lidocaine and Mepivacaine: 1 mL of 8.4% NaHCO3 per 10 mL of local anesthetic.
• Bupivacaine: 0.1 mL of 8.4% NaHCO3 per 10 mL of local anesthetic (bupivacaine precipitates out of solution into insoluble crystals if over-alkalinized due to its low aqueous solubility).

Alkalinization elevates the pH of the commercial mixture toward physiologic neutrality, dramatically increasing the proportion of uncharged free base (B). This accelerates the rate of axonal membrane permeation, hastening the onset of sensory blockade by 3 to 5 minutes, deepening the block intensity, and significantly mitigating the sharp burning pain experienced by the patient during local subcutaneous infiltration.

---

Drug-Induced Methemoglobinemia

Methemoglobinemia is a life-threatening hematologic complication associated primarily with two local anesthetics:

• Prilocaine (Citanest): Metabolized in the liver to ortho-toluidine, a potent oxidizing agent.
• Benzocaine (Cetacaine, Hurricaine): A topical ester spray commonly used for mucosal anesthesia prior to awake endotracheal intubation, upper endoscopy, and transesophageal echocardiography (TEE).

Pathophysiology & Clinical Recognition

Normal hemoglobin contains iron in the ferrous state (Fe2+), which reversibly binds oxygen. Ortho-toluidine and benzocaine oxidize ferrous iron into the ferric state (Fe3+), forming methemoglobin (MetHb):

1. Loss of Oxygen-Carrying Capacity: Ferric iron cannot bind oxygen.
2. Allosteric Leftward Shift: The presence of ferric iron in one or more heme subunits alters hemoglobin tetramer conformation, locking the remaining ferrous subunits into a high-affinity relaxed (R) state. This prevents the offloading of oxygen to peripheral tissues, inducing severe tissue hypoxia.
3. Refractory Cyanosis: Patients manifest a striking, slate-gray or brownish-blue perioral and nailbed cyanosis that is completely unresponsive to 100% inspired oxygen (FiO2 1.0).
4. Pulse Oximeter Fixation at ~85%: Methemoglobin absorbs equal quantities of red light (660 nm) and infrared light (940 nm). Because pulse oximeters calculate SpO2 based on the 660/940 nm absorption ratio (an R-value of 1.0), the monitor displays a falsely fixed saturation reading of ~85%, regardless of whether the true arterial oxygen saturation is 100% or 50%.
5. Chocolate-Brown Blood: Arterial blood drawn during a blood gas analysis displays a characteristic dark, chocolate-brown color that fails to turn bright red when exposed to air.

Definitive Antidote: Methylene Blue

Diagnosis is confirmed using co-oximetry, which measures light absorption at multiple distinct wavelengths to accurately quantify the methemoglobin fraction. Clinical treatment is indicated when MetHb levels exceed 20% to 30% or at lower levels if the patient manifests cardiac or neurologic symptoms:

• Pharmacologic Agent: Methylene Blue.
• Dosing: 1 to 2 mg/kg IV administered slowly over 5 minutes.
• Mechanism: Methylene blue acts as an exogenous electron donor. In the presence of intracellular NADPH, it is reduced by NADPH-methemoglobin reductase to leukomethylene blue, which then non-enzymatically transfers electrons to reduce ferric iron (Fe3+) back to active ferrous iron (Fe2+).
• Critical Contraindication: In patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, erythrocytes cannot generate sufficient NADPH. Administering methylene blue in G6PD deficiency is ineffective and provokes massive, life-threatening acute intravascular hemolytic anemia. Refractory cases or G6PD-deficient patients require hyperbaric oxygen therapy, high-dose intravenous ascorbic acid (vitamin C), or exchange transfusion.

---

Local Anesthetic Systemic Toxicity (LAST)

Local Anesthetic Systemic Toxicity (LAST) is a life-threatening complication resulting from supratherapeutic plasma concentrations of local anesthetic, caused by either accidental direct intravascular injection or rapid systemic vascular absorption from highly vascular tissue planes.

Tissue Vascularity & Absorption Hierarchy

The rate of vascular uptake and resulting peak plasma concentration (Cmax) depends on the intrinsic vascularity of the anatomical injection site. Technologists must memorize the hierarchy of systemic absorption, ranked from highest to lowest peak blood levels:

INTRAVENOUS (Highest Risk)
      |
      v
TRACHEAL (Topical Mucosal)
      |
      v
INTERCOSTAL (Intercostal Nerve Block)
      |
      v
CAUDAL (Caudal Epidural Space)
      |
      v
PARACERVICAL (Paracervical Block)
      |
      v
EPIDURAL (Lumbar / Thoracic Epidural)
      |
      v
BRACHIAL PLEXUS (Interscalene / Supraclavicular / Axillary)
      |
      v
SCIATIC / FEMORAL (Lower Extremity Blocks)
      |
      v
SUBCUTANEOUS (Infiltration / Lowest Risk)

(Clinical Mnemonic: "I Think I Can Please Every Beautiful Subcutaneous Site" -> Intravenous, Tracheal, Intercostal, Caudal, Paracervical, Epidural, Brachial plexus, Sciatic/femoral, Subcutaneous).

Clinical Progression of LAST

Systemic toxicity typically manifests as a progressive biphasic cascade, initially affecting the central nervous system (which is exquisitely sensitive to local anesthetic concentrations) before progressing to catastrophic cardiovascular collapse:

EARLY CNS PRODROME      -->      CNS EXCITATION      -->      CNS DEPRESSION      -->      CARDIOVASCULAR COLLAPSE
Perioral numbness                Muscle twitching              Stupor                   Conduction blocks (PR/QRS)
Metallic taste                   Tremors                       Coma                     Severe bradycardia
Tinnitus, visual changes         Tonic-clonic seizures         Apnea                    Ventricular tachycardia / VF
Slurred speech, agitation                                                               Asystole / Shock

1. Early CNS Excitation / Prodrome: Initial symptoms arise from the selective blockade of cortical inhibitory interneurons, leaving excitatory NMDA pathways unopposed. Manifests as perioral numbness, tongue paresthesia, metallic taste, tinnitus, lightheadedness, auditory ringing, blurred vision, dysphoria, shivering, and slurred speech.
2. Seizure Phase: Rapid progression to generalized tonic-clonic seizures, severe metabolic and respiratory acidosis, and profound hypoxemia.
3. Late CNS Depression: As plasma concentrations rise further, both inhibitory and excitatory pathways are extinguished, leading to obtundation, coma, loss of airway reflexes, and respiratory arrest (apnea).
4. Cardiovascular Collapse: Local anesthetics bind cardiac sodium channels (inhibiting Phase 0 depolarization), L-type calcium channels, and cardiac pacemaker cells. This induces widening of the QRS complex, prolonged PR interval, severe sinus bradycardia, atrioventricular heart blocks, polymorphic ventricular tachycardia (Torsades de pointes), ventricular fibrillation, refractory vasodilation, profound myocardial depression, and asystole.

Bupivacaine Cardiotoxicity: The CC/CNS Ratio

While all local anesthetics can cause toxicity, bupivacaine is uniquely notorious for lethal cardiotoxicity. Bupivacaine is exceptionally lipophilic and dissociates from cardiac sodium channels approximately 10 times slower than lidocaine during diastole ("fast-in, slow-out" receptor kinetics). This prolonged receptor occupancy promotes catastrophic re-entrant ventricular dysrhythmias.

The ratio of the dose required to produce cardiovascular collapse compared to the dose producing seizures is termed the CC/CNS ratio:

• Lidocaine CC/CNS Ratio = ~7.0: Massive doses are required to induce cardiac arrest; extensive CNS warning signs (prodrome, seizures) precede circulatory collapse.
• Bupivacaine CC/CNS Ratio = ~2.0: The margin of safety between CNS excitation and lethal cardiac arrest is extremely narrow. Inadvertent intravenous bolus injection of bupivacaine can trigger sudden, refractory ventricular fibrillation and asystole without any preceding CNS warning symptoms.

---

The ASRA-Pain Medicine LAST Protocol

The American Society of Regional Anesthesia and Pain Medicine (ASRA) publishes the standard clinical management checklist for LAST resuscitation. Anesthesia technologists must know every step of this algorithm and immediately locate the dedicated LAST Rescue Cart / Kit containing 20% lipid emulsion.

+-----------------------------------------------------------------------------+
|                   ASRA LAST MANAGEMENT RESUSCITATION ALGORITHM               |
+-----------------------------------------------------------------------------+
                                      |
                                      v
  1. STOP LOCAL ANESTHETIC INJECTION IMMEDIATELY
     - Call for help and shout for the LAST Rescue Cart & 20% Lipid Emulsion.
     - Alert nearest cardiac surgical / perfusion team for ECMO / CPB backup.
                                      |
                                      v
  2. AIRWAY & VENTILATION (PRIORITY ONE)
     - Ventilate with 100% FiO2. Secure airway via endotracheal intubation if needed.
     - CRITICAL: Prevent hypoxia, hypercapnia, and acidosis.
     - Hypercapnia and acidosis worsen LAST by increasing cerebral blood flow,
       elevating free active drug levels, and lowering seizure thresholds.
                                      |
                                      v
  3. SEIZURE SUPPRESSION
     - First-Line: BENZODIAZEPINES (Midazolam 1-2 mg IV titrated).
     - AVOID large doses of Propofol in hemodynamically unstable patients
       (propofol is a potent myocardial depressant and vasodilator).
     - Succinylcholine (0.5-1 mg/kg) may be used to abolish muscle contractions
       to facilitate oxygenation and ventilation (does not stop brain seizures).
                                      |
                                      v
  4. 20% LIPID EMULSION (INTRALIPID) RESUSCITATION
     - INITIAL BOLUS: 100 mL over 2-3 min if >70 kg; 1.5 mL/kg over 2-3 min if <70 kg.
     - CONTINUOUS INFUSION: 0.25 mL/kg/min immediately following bolus (~18 mL/min).
     - REPEAT BOLUS: Repeat 1.5 mL/kg bolus q3-5 min (up to 2 additional times)
       if cardiovascular instability or arrest persists.
     - ESCALATE INFUSION: Increase infusion to 0.5 mL/kg/min if hypotension continues.
     - MAXIMUM CUMULATIVE DOSE: 12 mL/kg over the first 30 minutes.
                                      |
                                      v
  5. ADVANCED CARDIAC LIFE SUPPORT (ACLS) MODIFICATIONS IN LAST
     - EPINEPHRINE: REDUCE individual boluses to < 1 mcg/kg (e.g., 10 to 50 mcg IV).
       DO NOT administer standard ACLS 1 mg epinephrine doses! High epinephrine doses
       impair lipid resuscitation, elevate afterload, and trigger arrhythmias.
     - STRICTLY AVOID: Vasopressin (worsens pulmonary edema and outcomes),
       Calcium Channel Blockers, Beta-Blockers, and Local Anesthetics (lidocaine
       and procainamide are strictly contraindicated as antiarrhythmics).
     - VENTRICULAR ARRHYTHMIAS: Treat with AMIODARONE (300 mg IV first dose).
     - REFRACTORY COLLAPSE: Initiate emergent Cardiopulmonary Bypass (ECMO/CPB).

Mechanisms of Lipid Emulsion Therapy ("Intralipid Rescue")

Twenty-percent intravenous lipid emulsion reverses local anesthetic toxicity through three distinct, synergistic mechanisms:

1. The "Lipid Sink" (Scavenger Hypothesis): Infused lipid droplets generate a massive, hydrophobic intravascular compartment. Highly lipophilic local anesthetics (especially bupivacaine and ropivacaine) partition preferentially into the intravascular lipid droplet core, stripping the toxic drug away from cardiac myocytes and brain tissue down a concentration gradient.
2. Metabolic Rescue: Toxic local anesthetic concentrations inhibit carnitine acyltransferase-1 (CAT-1) and halt mitochondrial fatty acid beta-oxidation within cardiomyocytes. Lipid emulsion provides abundant free fatty acid substrates, restoring mitochondrial ATP synthesis and reversing myocardial contractile failure.
3. Direct Cardiotonic & Membrane Effects: High-concentration lipid emulsion directly activates voltage-gated L-type calcium channels, increases intracellular calcium transit, stimulates vascular endothelial nitric oxide pathways, and activates glycogen synthase kinase-3beta (GSK-3beta) survival cascades.

---

Local Anesthetic Clinical Reference & Dosing Limits

Topical EMLA Cream (Eutectic Mixture of Local Anesthetics)

The ASATT pharmacology outline lists EMLA with the other local anesthetics. EMLA cream contains lidocaine 2.5% and prilocaine 2.5%. In the oil phase of the cream, the two amides form a 1:1 eutectic mixture whose melting point is below room temperature, so both drugs exist as a liquid oil rather than crystals. That liquid form penetrates intact skin better than either drug applied alone in crystalline form.

Application Rules from the U.S. Label

For infants and children, the label caps dose, area, and application time by age and weight:

Safety Points

• Methemoglobinemia: Prilocaine is metabolized to ortho-toluidine. Risk is higher with glucose-6-phosphate dehydrogenase (G6PD) deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months, and oxidizing drugs. The label says not to use EMLA in neonates born before 37 weeks of gestation or in infants under 12 months who are receiving methemoglobin-inducing drugs.
• Contraindication: Known sensitivity to amide local anesthetics or another component of the cream.
• Where not to apply: Open wounds, near the eyes, or anywhere the cream could pass beyond the tympanic membrane into the middle ear.
• Additive effects: Doses from other lidocaine or prilocaine products add together, and patients taking class III antiarrhythmics such as amiodarone need close observation.

Technologist Workflow

EMLA is most often requested before IV starts in children or needle-anxious adults. Because intact skin needs at least an hour under occlusion, the cream goes on in preoperative holding and the application time can be marked on the dressing; the label notes that clinical trials usually prepared two sites in case the first cannulation failed. Before cannulation, the dressing is removed, the cream is wiped off, and the site is cleaned with antiseptic. Transient blanching followed by redness at the site is an expected local effect.